NEWS SAT
Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer
Corvus Pharmaceuticals (NASDAQ: CRVS) presented new data at SITC's 39th Annual Meeting showing ciforadenant's potential to overcome resistance to anti-PD1 immunotherapy in metastatic castration resistant prostate cancer (mCRPC). The research, selected as a Top 100 abstract, identified SPP1+ myeloid cells as critical mediators of immunotherapy resistance. Clinical trial results showed that when ciforadenant was combined with atezolizumab, 5 of 24 patients (21%) achieved PSA partial responses, compared to 1 of 11 (9%) with ciforadenant monotherapy. The study demonstrated that ciforadenant treatment reduced immunosuppression and enhanced sensitivity to anti-PD1 therapy.
Positive
▪️Clinical trial showed 21% response rate in combination therapy vs 9% in monotherapy
▪️Research selected as Top 100 abstract at SITC Annual Meeting
▪️Demonstrated potential to overcome immunotherapy resistance in mCRPC
▪️Clinical trial showed 21% response rate in combination therapy vs 9% in monotherapy
▪️Research selected as Top 100 abstract at SITC Annual Meeting
▪️Demonstrated potential to overcome immunotherapy resistance in mCRPC
Negative
▪️Low overall response rates in both monotherapy (9%) and combination therapy (21%)
▪️Study to small patient sample size (35 patients total)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2544Followers
107Following
28KVisitors
Follow